Drug Profile

CNTX 6970

Alternative Names: CNTX-6970

Latest Information Update: 27 Jun 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class Anti-inflammatories; Non-opioid analgesics; Small molecules
Mechanism of Action CCR2 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Inflammatory pain

Most Recent Events

11 Jun 2024 Massachusetts General Hospital completes phase-II clinical trial in Inflammatory pain (In adults, In the elderly) in USA (PO) (NCT05025787)
07 Dec 2022 Phase II development in Inflammatory pain is ongoing in USA (PO) (Centrexion Therapeutics pipeline, December 2022)
25 Oct 2021 Phase-II clinical trials in Inflammatory pain (In adults, In the elderly) in USA (PO) (NCT05025787)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com